Drug – bio-affecting and body treating compositions – Lymphokine
Reexamination Certificate
2009-07-14
2010-11-02
Nickol, Gary B. (Department: 1647)
Drug, bio-affecting and body treating compositions
Lymphokine
C424S196110, C530S351000, C530S402000, C435S069400, C514S002600
Reexamination Certificate
active
07824669
ABSTRACT:
The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby. Also disclosed are therapeutic methods for using the cysteine variants of the invention.
REFERENCES:
patent: 4588585 (1986-05-01), Mark et al.
patent: 4636463 (1987-01-01), Altman et al.
patent: 4855238 (1989-08-01), Gray et al.
patent: 5162111 (1992-11-01), Grabstein et al.
patent: 5166322 (1992-11-01), Shaw et al.
patent: 5178855 (1993-01-01), Bonnem
patent: 5206344 (1993-04-01), Katre et al.
patent: 5208158 (1993-05-01), Bech et al.
patent: 5229496 (1993-07-01), Deeley et al.
patent: 5391485 (1995-02-01), Deeley et al.
patent: 5393870 (1995-02-01), Deeley et al.
patent: 5578301 (1996-11-01), Myers
patent: 5602007 (1997-02-01), Dunn et al.
patent: 5629283 (1997-05-01), Nicola et al.
patent: 5720952 (1998-02-01), Clark et al.
patent: 5766897 (1998-06-01), Braxton
patent: 5849535 (1998-12-01), Cunningham et al.
patent: 5891429 (1999-04-01), Clark et al.
patent: 5895646 (1999-04-01), Wang
patent: 5908763 (1999-06-01), Clark et al.
patent: 5916773 (1999-06-01), Mele et al.
patent: 5942221 (1999-08-01), Clark et al.
patent: 6287557 (2001-09-01), Boursnell et al.
patent: 6608183 (2003-08-01), Cox, III
patent: 6753165 (2004-06-01), Cox et al.
patent: 7148333 (2006-12-01), Cox, III
patent: 7153943 (2006-12-01), Cox, III et al.
patent: 7214779 (2007-05-01), Cox, III
patent: 7232885 (2007-06-01), Cox, III
patent: 7253267 (2007-08-01), Cox, III
patent: 7270809 (2007-09-01), Cox, III
patent: 7306931 (2007-12-01), Rosendahl et al.
patent: 7309781 (2007-12-01), Cox, III
patent: 7314921 (2008-01-01), Cox, III
patent: 7345149 (2008-03-01), Cox, III
patent: 7345154 (2008-03-01), Cox, III
patent: 7399839 (2008-07-01), Cox et al.
patent: 7495087 (2009-02-01), Cox, III
patent: 2003/0166865 (2003-09-01), Cox, III
patent: 2004/0230040 (2004-11-01), Cox, III
patent: 2005/0026834 (2005-02-01), Cox, III
patent: 2005/0214254 (2005-09-01), Cox, III
patent: 2007/0253929 (2007-11-01), Cox, III
patent: 2008/0076706 (2008-03-01), Cox
patent: 2008/0219950 (2008-09-01), Cox
patent: 2008/0317713 (2008-12-01), Cox
patent: 2009/0060863 (2009-03-01), Cox
patent: 2066370 (1996-04-01), None
patent: 0355460 (1990-02-01), None
patent: 0458064 (1991-11-01), None
patent: 4-507099 (1992-12-01), None
patent: 5-268983 (1993-10-01), None
patent: 6-510904 (1994-12-01), None
patent: 9-503396 (1997-04-01), None
patent: 10-507080 (1998-07-01), None
patent: WO 90/12874 (1990-11-01), None
patent: WO 90/13310 (1990-11-01), None
patent: WO 93/00109 (1993-01-01), None
patent: WO 93/06217 (1993-04-01), None
patent: WO 94/12219 (1994-06-01), None
patent: WO 94/22466 (1994-10-01), None
patent: WO 95/11987 (1995-05-01), None
patent: WO 95/32003 (1995-11-01), None
patent: WO 95/34326 (1995-12-01), None
patent: WO 96/04385 (1996-02-01), None
patent: WO 96/11949 (1996-04-01), None
patent: WO 96/31537 (1996-10-01), None
patent: WO 96/36362 (1996-11-01), None
patent: WO 97/11370 (1997-03-01), None
patent: WO 98/25971 (1998-06-01), None
patent: WO 98/37200 (1998-08-01), None
Walter M.R. et al. Crystal structure of a complex between interferon-gamma and its soluble high-affinity receptor. Nature. 2000. vol. 376, p. 230-235.
Watson JD-Molecular Biology of the gene, third edition, WA Benjamin, eds. ISBN 0-8053-9609-8, p. 367, 1977.
U.S. Appl. No. 12/001,639, filed Dec. 11, 2007, Rosendahl et al.
Bazan et al., “Unraveling the Structure of IL-2” Science, vol. 257 No. 5068, pp. 410-413 (Jul. 1992).
Bazan, “Haemopoietic receptors and helical cytokines” Immunology Today, 11:350-354 (1990).
Bowie et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions” Science, vol. 247 No. 4948, pp. 1306-1310 (Mar. 1990).
Campbell et al., “Pegylated peptides V” J. Peptide Res., 49:527-537 (1997).
Cantrell et al., “Cloning, sequence, and expression of a human granulocyte/macrophage colony-stimulating factor.” Proceedings of the National Academy of Sciences, USA, vol. 82 No. 18, pp. 6250-6254 (1985).
Clark-Lewis et al., “Structure-function studies of human granulocyte-macrophage colony-stimulating factor. Identification of residues required for activity” Journal of Immunology, vol. 141 No. 3, pp. 881-889 (Aug. 1988).
Cunningham BC, Wells JA. “High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis” Science. 244:1081-5, (1989).
Cunningham et al., “Receptor and Antibody Epitopes in Human Growth Hormone Identified by Homolog-Scanning Mutagenesis” Science, 243:1330-1336 (1989).
Diederichs et al., “Novel fold and putative receptor binding site of granulocyte-macrophage colony-stimulating factor.” Science, vol. 254 No. 5039, pp. 1779-1782 (1991).
Ganser et al., “The effect of recombinant human granulocyte-macrophage colony-stimulating factor on neutropenia and related morbidity in chronic severe neutropenia” Annals of Internal Medicine, vol. 111 No. 11, pp. 887-892 (Dec. 1989).
Goodson and Katre, “Site-Directeed Pegylation of Recombinant Interleukin-2 at its Glycosylation Site” Bio/Technology, 8:343-346 (1990).
Knulsi et al., “Polyethylene glycol (PEG) modification of granulocyte-macrophage colony stimulating factor (GM-CSF) enhances neutrophil priming activity but not colony stimulating activity” British Journal of Haematology, vol. 82 No. 4, pp. 654-663 (1992).
Lee et al., “Isolation of cDNA for a human granulocyte-macrophage colony-stimulating factor by functional expression in mammalian cells” Proceedings of the National Academy of Sciences, USA, vol. 82 No. 13, pp. 4360-4364 (1985).
Mori et al., “Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) and rhG-CSF in the treatment of a child with severe chronic neutropenia” Blood, vol. 84 No. 9, pp. 3244-3245 (Nov. 1994).
Mott and Campbell, “Four-helix bundle growth factors and their receptors: protein-protein interactions” Curr Opin Struct Biol, 5:114-121 (1995).
Olins P.O. et al: ‘Saturation muatgenesis of human interleukin-3’ Journal of Biological Chemistry vol. 270, No. 40, Oct. 6, 1996, pp. 23754-23760.
Rozwarski et al., “Refined crystal structure and mutagenesis of human granulocyte-macrophage colony-stimulating factor.” Proteins, vol. 26 No. 3, pp. 304-313 (Nov. 1996).
Shanafelt et al., “Identification of critical regions in mouse granulocyte-macrophage colony-stimulating factor by scanning-deletion analysis” Proceedings of the National Academy of Sciences, USA, vol. 86, pp. 4872-4876 (1989).
Sprang and Bazan, “Cytokine structural taxonomy and mechanisms of receptor engagement” Curr. Opin. Struct. Biol., 3:815-827 (1993).
Walter et al., “Three-dimensional structure of recombinant human granulocyte-macrophage colony-stimulating factor.” J. Mol. Biol., 224:1075-1085 (1992).
Wells, “Hematopoietic Receptor Complexes” Ann. Rev. Biochem., 65:609-634 (1996).
Zalipsky, “Chemistry of polyethylene glycol conjugates with biologically active molecules” Adv. Drug Delivery Reviews, 16:157-182 (1995).
Zurawaki et al. “Definition and spatial location of mouse interleukin-2 residues that interact with the heterotrmeric receptor”, Embo Journal 12, 5113-5119, 1993.
Watson JD, Molecular
Cox, III George N.
Doherty Daniel H.
Bolder Biotechnology Inc.
Nickol Gary B.
Sheridan & Ross P.C.
Stoica Elly-Gerald
LandOfFree
In vivo stimulation of peripheral blood progenitor cells by... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with In vivo stimulation of peripheral blood progenitor cells by..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and In vivo stimulation of peripheral blood progenitor cells by... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4232305